Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005–2022: an observational study
The time interval from regulatory approval to NRDL listing in China decreased over time. However, more than half of cancer drug indications listed for public insurance reimbursement did not have confirmed survival gain or substantial clinical benefits at the time of NRDL inclusion or after. Payers should give sufficient consideration to clinical benefit evidence when making reimbursement and disinvestment decisions to avoid wasteful spending of public health insurance funds.
Authors
- Huangqianyu Li (ORCID: https://orcid.org/0000-0001-8744-0276)
- Luwen Shi (ORCID: https://orcid.org/0000-0003-2683-6685)
- Huseyin Naci (ORCID: https://orcid.org/0000-0002-7192-5751)
- Jinyu Chen
- Xiaodong Guan (ORCID: https://orcid.org/0000-0002-1290-3827)
- Yichen Zhang (ORCID: https://orcid.org/0000-0001-7093-1044)
- Anita K. Wagner
Institutions
- Harvard University (US)
- Chinese University of Hong Kong (HK)
- Peking University (CN)
- Harvard Pilgrim Health Care (US)
- University of Hong Kong (HK)
- London School of Economics and Political Science (GB)
Publication Details
- Journal
- BMJ evidence-based medicine
- Published
- 2025-10-12
- DOI
- https://doi.org/10.1136/bmjebm-2025-113722
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00